Clinical Trial

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

Study acronym: CLIMB
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study is to find out if the antihistamine, clemastine, can make the white matter in the brain better in older adults with depression. The study will also determine whether this improvement can make antidepressant treatment work better, reduce depressive symptoms, and improve memory and thinking.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-09-06; most recent amendment 2026-06-26.
Status change: Not Yet Recruiting → Recruiting 2026-06-26
Trial Details
NCT Number NCT06591091
Lead Sponsor University of Illinois at Chicago
Collaborators: Cures Within Reach
Conditions Depression
Enrollment 80 participants
Start Date 2025-12-10
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-30